All-trans-retinoic acid treatment results in a 50–60% reduction in ALDH activity and proteins of both isozymes, ALDH1A1 and ALDH3A1, leading to the increased sensitization of ALDH1+ cancer cells to chemotherapy. The gene discussed is ALDH1A1; the disease is cancer.